Menopur

Menotrophin, the active ingredient in Menopur, is a gonadotropin presented as a lyophilized powder for injection for subcutaneous use. It provides follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity to stimulate ovarian follicular development and ovulation, addressing infertility due to anovulation and supporting controlled ovarian hyperstimulation in assisted reproductive technology cycles.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity for fertility treatment programs and patient‑centric care.

Menopur, a gonadotropin used in reproductive endocrinology, is indicated for the following clinical situations: - Infertility due to anovulation: induces follicular development to achieve ovulation. - Controlled ovarian hyperstimulation for assisted reproductive technology (ART): supports multiple follicle growth for IVF/ICSI cycles. - Ovarian stimulation for intrauterine insemination (IUI): enhances follicular response to improve pregnancy rates.

Menopur may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Injection site pain or erythema. - Mild abdominal discomfort or bloating. - Nausea or mild vomiting. - Breast tenderness or swelling.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome (OHSS). - Ovarian torsion. - Thromboembolic events. - Allergic reaction or anaphylaxis. - Multiple pregnancy. - Visual disturbances or sudden headache.

When using Menopur, clinicians should observe several safety measures. - Monitor ovarian response: perform serial ultrasound and estradiol assessments. - Assess OHSS risk: consider patient age, BMI, and prior response. - Adjust dose based on individual response and follicular development. - Contraindicated in pregnancy: avoid use once conception is confirmed. - Avoid in patients with uncontrolled thyroid disease or severe ovarian pathology. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur may interact with other agents that influence ovarian response or coagulation.

Major Interactions (Avoid): - Concurrent use of other gonadotropins may amplify OHSS risk. - Simultaneous hCG administration for ovulation trigger can increase severe OHSS. - Estrogen‑containing contraceptives may reduce efficacy of stimulation. - Anticoagulants may heighten bleeding risk during oocyte retrieval.

Moderate Interactions (Monitor Closely): - NSAIDs can mask pain symptoms of OHSS; monitor closely. - Corticosteroids may alter follicular dynamics; adjust monitoring. - Thyroid hormone therapy may require dose adjustment of Menopur. - Anti‑emetic agents may affect patient comfort but not efficacy.